Early detection and prompt medical intervention matter enormously.
En las primeras semanas de julio de 2023, Perú declaró emergencia sanitaria nacional ante un aumento inusual de casos de síndrome de Guillain-Barré, una enfermedad neurológica en la que el propio sistema inmunitario ataca los nervios del cuerpo. Con 182 casos registrados, 31 hospitalizaciones y 4 muertes desde enero, el gobierno activó protocolos de excepción y comprometió la compra de cinco mil viales de inmunoglobulina. Es el tipo de momento en que una nación debe elegir entre la inercia burocrática y la acción colectiva; Perú eligió actuar, reconociendo que el tiempo, en enfermedades como esta, es tan decisivo como el tratamiento mismo.
- Un aumento acelerado de casos de Guillain-Barré en pocas semanas obligó al ministro de Salud César Vásquez a declarar emergencia nacional antes de que la situación se saliera de control.
- Con cuatro muertes y decenas de hospitalizaciones, la enfermedad —que puede avanzar de debilidad muscular a parálisis total— exige intervención médica urgente para evitar daños irreversibles.
- El gobierno comprometió la adquisición de cinco mil viales de inmunoglobulina, el tratamiento clave, a distribuir a través del sistema centralizado de abastecimiento estratégico en salud.
- El desafío más crítico no es Lima, donde los hospitales ya fueron reforzados, sino las regiones provinciales, donde la capacidad de diagnóstico y atención aún está siendo construida contra el reloj.
- La ventana de noventa días es tanto una medida de emergencia como una declaración pública: el Estado peruano reconoce la crisis y asume la responsabilidad de responder con coordinación y equidad territorial.
A comienzos de julio de 2023, el gobierno peruano declaró emergencia sanitaria nacional de noventa días ante un preocupante aumento de casos de síndrome de Guillain-Barré, una enfermedad neurológica poco común en la que el sistema inmunitario ataca las células nerviosas que controlan el movimiento muscular. La declaratoria vino acompañada de una medida concreta: la compra de cinco mil viales de inmunoglobulina, el tratamiento principal para la enfermedad, a distribuirse a través del organismo estatal de abastecimiento en salud.
Al 7 de julio, Perú acumulaba 182 casos confirmados desde enero, con 31 pacientes hospitalizados y 4 fallecidos. El ministro de Salud, César Vásquez, explicó que la emergencia permitiría agilizar la adquisición de insumos y garantizar que los hospitales —especialmente en Lima— contaran con los recursos necesarios. Vásquez visitó personalmente el Instituto de Ciencias Neurológicas para observar la atención de los pacientes y recorrió sus distintas áreas junto al director Jorge Medina, subrayando en redes sociales la necesidad de una "salud con inclusión social para todos".
El síndrome de Guillain-Barré, aunque raramente fatal, puede progresar hasta la parálisis e incluso comprometer la respiración en los casos más graves. La mayoría de los pacientes se recupera, pero el tiempo es determinante: quienes reciben inmunoglobulina de forma temprana tienen muchas más posibilidades de evitar secuelas permanentes.
El Ministerio de Salud y el Instituto Nacional de Salud comparten ahora la responsabilidad de ejecutar el plan de acción. El reto principal es doble: distribuir los viales a tiempo y capacitar al personal médico en regiones provinciales, donde la infraestructura hospitalaria es más limitada. Los noventa días de emergencia son, en esencia, una carrera contra el reloj para que ningún paciente, sin importar dónde viva, llegue demasiado tarde al tratamiento.
Peru's government moved to declare a national health emergency in early July 2023, responding to a sharp rise in cases of Guillain-Barré syndrome, a rare neurological disorder in which the body's own immune system begins attacking nerve cells. The declaration, set to remain in effect for ninety days, came with a concrete commitment: the purchase of five thousand vials of immunoglobulin, the primary treatment for the condition, to be distributed through the country's central procurement agency for strategic health resources.
By July 7th, Peru had recorded one hundred eighty-two confirmed cases since the start of the year. Of those, thirty-one patients required hospitalization, and four had died. The numbers represented a troubling acceleration that forced the hand of César Vásquez, Peru's health minister, who explained that the emergency declaration would streamline the acquisition of treatment supplies and ensure hospitals—particularly those in Lima—had what they needed to respond. "There has been a significant increase in recent weeks that compels us to act," Vásquez said, noting that the government had already worked to secure adequate treatment in Lima's hospitals and was now training and equipping facilities in provincial regions to handle the surge.
Guillain-Barré syndrome is not a common diagnosis. It occurs when the immune system misfires, attacking the nerve cells that control muscle movement. The result is progressive weakness, sometimes advancing to paralysis. Most people who contract it recover fully, though some experience lasting nerve damage. In the rarest cases, the disease proves fatal—typically when it affects the muscles needed for breathing. This is why early detection and prompt medical intervention matter enormously. A person who recognizes symptoms and reaches a hospital quickly has a far better chance of receiving immunoglobulin therapy before the condition worsens.
Vásquez visited two patients hospitalized at Peru's Institute of Neurological Sciences to observe their care firsthand. He toured the facility's storage areas, medical records, wards, outpatient clinics, emergency department, pharmacy, and intensive care unit, alongside the institute's director, Jorge Medina. In a Facebook post, Vásquez emphasized the quality of care the patients were receiving and called for "health with social inclusion for all"—a reminder that access to treatment cannot be confined to the capital or to those with resources.
The Ministry of Health and the National Institute of Health now share responsibility for executing the emergency action plan. The challenge ahead is substantial: ensuring that five thousand vials of immunoglobulin reach the right hospitals at the right time, training medical staff across the country to recognize and treat the syndrome, and building capacity in provincial hospitals so that patients outside Lima do not face delays that could cost them their health or their lives. The ninety-day window is both a deadline and a signal—a statement that Peru's government recognizes this as a crisis requiring immediate, coordinated response.
Citas Notables
There has been a significant increase in recent weeks that compels us to act.— César Vásquez, Peru's health minister
La Conversación del Hearth Otra perspectiva de la historia
Why does Peru need to declare an emergency for a rare disease? Couldn't they just order the medicine?
Because immunoglobulin is expensive and in limited supply. A normal procurement process takes weeks. An emergency declaration lets them bypass red tape and buy five thousand vials at once through their central agency.
And the patients who are already sick—are they getting treated?
Some are. Thirty-one are hospitalized. But the real worry is the ones who haven't reached a hospital yet, or the ones in provinces where there's no immunoglobulin at all. Early treatment is everything with this disease.
What actually happens to someone with Guillain-Barré?
Their immune system attacks their own nerves. They get weak, sometimes paralyzed. Most recover, but some don't. A few die, usually because they can't breathe. It's why the health minister visited patients in the hospital—to show the system is paying attention.
Four deaths out of one hundred eighty-two cases—is that a lot?
For a rare disease, yes. And those are just the confirmed cases. The real concern is whether there are more cases out there that haven't been diagnosed yet, especially in rural areas.
What happens after the ninety days?
That depends on whether the cases keep rising or start to fall. If they fall, the emergency ends. If they don't, Peru will have to figure out why—whether it's an infection triggering the syndrome, or something else entirely.